BioDelivery Sciences price target raised to $7 from $6 at Roth Capital

Roth Capital increased its target on BioDelivery Sciences after the company reported positive pharmacokinetic data for its BNX treatment for opioid dependence. The firm thinks the stock could exceed its target if the company signs a partnership or files for approval of the drug. The firm maintains a Buy rating on the shares.

View Comments (0)